Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CEFTAZIDIME Cause Multiple-drug resistance? 35 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 35 reports of Multiple-drug resistance have been filed in association with CEFTAZIDIME (TAZICEF). This represents 1.1% of all adverse event reports for CEFTAZIDIME.

35
Reports of Multiple-drug resistance with CEFTAZIDIME
1.1%
of all CEFTAZIDIME reports
15
Deaths
17
Hospitalizations

How Dangerous Is Multiple-drug resistance From CEFTAZIDIME?

Of the 35 reports, 15 (42.9%) resulted in death, 17 (48.6%) required hospitalization, and 3 (8.6%) were considered life-threatening.

Is Multiple-drug resistance Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CEFTAZIDIME. However, 35 reports have been filed with the FAERS database.

What Other Side Effects Does CEFTAZIDIME Cause?

Drug ineffective (518) Off label use (266) Condition aggravated (228) Septic shock (200) Acute kidney injury (191) Pyrexia (176) Endophthalmitis (128) Multiple organ dysfunction syndrome (124) Neutropenia (123) Drug reaction with eosinophilia and systemic symptoms (121)

What Other Drugs Cause Multiple-drug resistance?

LEVETIRACETAM (1,378) LACOSAMIDE (739) VALPROIC ACID (622) TOPIRAMATE (521) CLOBAZAM (486) LAMOTRIGINE (418) PHENOBARBITAL (406) PHENYTOIN (337) CARBAMAZEPINE (299) PERAMPANEL (258)

Which CEFTAZIDIME Alternatives Have Lower Multiple-drug resistance Risk?

CEFTAZIDIME vs CEFTIBUTEN CEFTAZIDIME vs CEFTOLOZANE\TAZOBACTAM CEFTAZIDIME vs CEFTRIAXONE CEFTAZIDIME vs CEFTRIAXONE\CEFTRIAXONE CEFTAZIDIME vs CEFUROXIME

Related Pages

CEFTAZIDIME Full Profile All Multiple-drug resistance Reports All Drugs Causing Multiple-drug resistance CEFTAZIDIME Demographics